# A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors

> **NCT07070232** · PHASE1,PHASE2 · RECRUITING · sponsor: **BioNTech SE** · enrollment: 980 (estimated)

## Conditions studied

- Advanced Solid Tumor

## Interventions

- **DRUG:** BNT326
- **DRUG:** Pumitamig
- **DRUG:** Itraconazole
- **DRUG:** Paroxetine

## Key facts

- **NCT ID:** NCT07070232
- **Lead sponsor:** BioNTech SE
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-08-12
- **Primary completion:** 2028-02
- **Final completion:** 2029-10
- **Target enrollment:** 980 (ESTIMATED)
- **Last updated:** 2026-03-12

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07070232

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07070232, "A Clinical Study to Test if an Investigational Treatment Called BNT326 is Safe and Potentially Beneficial When Used Alone or in Combination With Other Investigational Treatments Such as BNT327, for People With Advanced Malignant Tumors". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT07070232. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*